Vitamin K antagonists (VKA) are among the most widely prescribed drugs in the industrialized world.In thin mantel shelf fact, for decades, VKA have been the only orally available anticoagulant for the primary and secondary prevention of venous and arterial thrombotic events.Their efficacy has been widely demonstrated in s1229rs a series of studies carried out in the 1990s.Since the incidences of atrial fibrillation and venous thromboembolism increase exponentially with age, the number of anticoagulated patients is destined to increase.
This paper examines anticoagulation therapy management with particular attention to the use of VKA.